Global Survey Reveals How Plasma Donors Transform Lives of Patients Worldwide

Every few weeks, in donation centers across North America and Europe, thousands of people settle into reclining chairs while a machine separates a golden, straw-colored component from their blood and returns the rest to their veins. That component, plasma, is the raw material for a class of medicines that millions of patients cannot live without. As International Plasma Awareness Week begins on October 5, a new global survey conducted by the Plasma Protein Therapeutics Association and analyzed by the research firm SSRS offers one of the most detailed portraits yet of the people who depend on these therapies, and of the gratitude they feel toward the donors who make them possible. The findings arrive at a moment when demand for plasma-derived medicines continues to climb worldwide, making the connection between donor and patient more consequential than ever.

The survey gathered 1,167 completed interviews online via SurveyMonkey, with data provided to SSRS for formal analysis in August 2026. Respondents included patients, caregivers, healthcare providers, and patient advocates from around the world, giving the results a breadth that few single-condition studies can match. What emerges is a picture of medical dependence that is both chronic and intimate: roughly two in three respondents reported that they, or someone they care for, receive plasma-derived medicines at least once a month, and 41 percent said treatment occurs weekly. For these families, plasma therapy is not an occasional intervention but a recurring rhythm of life, scheduled around infusions, clinic visits, and the constant logistics of maintaining a supply of medicine that exists only because someone else volunteered to donate.

The conditions that drive this dependence are diverse, but they share a common thread: the body’s own biochemistry has failed in a way that only donated human plasma can reliably correct. Nearly half of respondents said they or someone they care for receive plasma-derived medicines for an immunodeficiency, 18 percent for a bleeding or blood disorder, 16 percent for a neurological condition, and 15 percent for a lung-related illness. Primary immunodeficiencies, a group of more than 400 inherited disorders in which part of the immune system is missing or malfunctioning, are among the most prominent indications. Patients with these conditions lack adequate antibodies of their own, and the immunoglobulin therapies derived from pooled donor plasma effectively replace that missing molecular armor, shielding them from infections that most people shrug off without noticing.

The technical journey from a donor’s arm to a patient’s infusion bag is one of the more remarkable processes in modern biomedicine. Once collected, plasma from thousands of individual donations is pooled and subjected to fractionation, a carefully sequenced separation process that exploits differences in protein solubility and behavior to isolate specific therapeutic components. Immunoglobulins, clotting factors such as Factor VIII for hemophilia, albumin for treating shock and burns, and other proteins are each extracted, purified, and subjected to multiple viral inactivation and removal steps. Because many of these proteins cannot yet be produced synthetically at scale, donated human plasma remains the only practical source. That biological reality is what binds a donor in Addison, Illinois, to a patient on another continent, and it is why the industry built around fractionation is often described as a unique sector of the biologics and biotechnology landscape.

The survey’s most striking finding concerns speed of effect. More than two-thirds of respondents, 69 percent, noticed a change in their health, or in the health of someone they care for, within a few months of beginning a plasma-derived medicine, and 26 percent noticed a change within just a few days. For clinicians who treat immunodeficiency or bleeding disorders, this rapid response is familiar territory: a child with hemophilia who receives a clotting factor concentrate can stop a spontaneous joint bleed within hours, and an immunodeficient patient beginning immunoglobulin replacement often reports a dramatic reduction in the frequency and severity of infections within the first months of therapy. The survey data translate that clinical observation into a population-level statistic, quantifying how quickly these biologics alter the daily experience of illness.

Confidence in the medicines themselves is correspondingly high. Fully 87 percent of patients expressed confidence in the safety and efficacy of plasma-derived therapies, a figure that reflects decades of incremental improvement in donor screening, pathogen detection, and manufacturing controls. Modern plasma products undergo nucleic acid testing for blood-borne viruses, hold periods that allow emerging infections to be detected before pools are released, and redundant viral clearance steps during fractionation. That layered safety architecture, developed and refined since the challenges of the 1980s, underpins the trust that patients report in the survey and allows these therapies to be delivered into veins on a weekly basis with a risk profile that patients and their physicians consider acceptable for lifelong use.

Gratitude emerges as the emotional throughline of the findings. More than three-quarters of respondents, 77 percent, described themselves as grateful to plasma donors, an expression that the survey’s sponsors hope will translate into more people rolling up their sleeves. Behind the statistic are individual stories that illustrate what the numbers mean in practice. Christy Savino, a plasma recipient diagnosed with a primary immunodeficiency, described the impact in personal terms: the therapy allows her family to make memories together, a gift of life she described as present in every moment of every day and traveling with the family wherever they go. Her husband, Antonio Savino, donates plasma regularly at a BioLife Plasma Services donation center in Addison, Illinois, in her honor, a concrete example of the donor-to-patient loop that the awareness week is designed to celebrate.

Patient advocacy organizations see the survey as an opportunity to widen the circle of people who understand where these medicines come from. Jorey Berry, President and CEO of the Immune Deficiency Foundation, noted that this year’s International Plasma Awareness Week campaign shines a light on people and families living with immunodeficiencies and other rare diseases, and emphasized that for many patients these medicines are not merely treatments but what makes everyday life possible. His message to potential donors is direct: every plasma donation matters deeply, and donating offers healthy people a tangible way to give patients the chance to live healthier, fuller lives. The campaign’s framing, that plasma powers possibility, is an attempt to convert abstract appreciation into the specific act of booking a donation appointment.

The scale of the enterprise behind these therapies is easy to underestimate. The Plasma Protein Therapeutics Association, which represents the manufacturers and collectors of plasma protein therapies, counts more than 1,000 plasma collection centers across North America and Europe among its members. Those members produce approximately 80 percent of the plasma protein therapies used in the United States and approximately 60 percent of those used in Europe. Meeting global demand requires millions of donations each year, because a single patient’s annual immunoglobulin supply can require donations from hundreds or even thousands of individual donors over the course of a year of fractionated production. The arithmetic of that supply chain explains why donor recruitment is a permanent, global public health effort rather than a one-time campaign.

For the patients and caregivers who answered the survey, the message that emerges is one of quiet, ongoing dependence paired with remarkable resilience. The age at which treatment began varied widely among respondents, though the largest share, 49 percent, said they or someone they care for first received a plasma-derived medicine between the ages of 36 and 64, indicating that these therapies enter lives at every stage, not only in childhood. What unites them is the experience of a medicine that works quickly, is trusted deeply, and exists only through the generosity of strangers. International Plasma Awareness Week, which runs through the week beginning October 5, asks the public to see that connection clearly: behind every vial of immunoglobulin or clotting factor is a person who took an hour to donate, and behind every donor is a patient whose ordinary day, and ordinary family memories, depend on it. Information about donation and patient stories is available at plasmaweek.org and through the association’s donation center locator.

Subject of Research: Global patient survey on the use, impact, and perceived safety of plasma-derived medicines and the role of plasma donors

Article Title: New global survey shines a light on the patients who rely on plasma-derived medicines—and the donors who make them possible

Article References: New global survey shines a light on the patients who rely on plasma-derived medicines—and the donors who make them possible. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: plasma donation, plasma-derived medicines, plasma protein therapeutics, primary immunodeficiency, immunoglobulin therapy, bleeding disorders, International Plasma Awareness Week, patient survey, SSRS, PPTA, fractionation, rare diseases